Who we are

Omnicin Therapeutics BV is a pre-clinical stage biopharmaceutical company, based in Groningen, The Netherlands. The company develops products that potentiate existing antibiotics and thus contributes to combatting the worldwide problem of multi-resistant bacteria. Omnicin’s primary product OTX003 is an inhalation formulation of a bismuth salt. We aim to demonstrate clinical safety and efficacy of this novel inhalation formulation in patients that receive their standard care of existing antibiotics against life-threatening resistant Pseudomonas aeruginosa infections.

The Problem

P. aeruginosa infections are a major challenge in healthcare, it is among the most common healthcare associated infections with high mortality

  • 1,000,000 Healthcare associated infections in Europe annually
  • 14% Of european isolates is resistant to at least 3 antibiotics
  • 35.8% Mortality of ventilator associated pneumonia when caused by MDR
    P. aeruginosa strain
  • 40,000 Healthcare costs per ICU patient with ventilator associated infection

P. aeruginosa is a bacterium that causes severe and chronic infections in for instance lungs. It is intrinsically very resistant against many currently used antibiotics and has a high associated mortality. It is one of the leading healthcare associated infections in Europe. It is estimated that in Europe alone 1 million healthcare associated infections caused by Pseudomonas occur annually. In cystic fibrosis (CF) patients these infections occur regularly and eventually 70% of CF patients will develop a chronic infection resulting in strong clinical decline. The WHO has categorized the development of new treatments against these infections as critical, being in their highest priority category.

Pipeline

Omnicin develops products that potentiate existing antibiotics and range from peptides to metal salts. OTX003, our primary product based on a bismuth salt interferes with the iron homeostasis of Pseudomonas aeruginosa and blocks multidrug pumps improving the effectiveness of currently used antibiotics and enabling the use of antibiotics currently ineffective against the target. This means that resistant bacteria can be attacked on a target that is currently not used in the clinic. Treatments based on new targets are medically highly desired. OTX003 is an inhalation formulation of a bismuth salt and can be used as an add-on inhalation therapy for patients that receive antibiotics against chronic lung infections.

The Team

  • Auke van Heel
    Dribbble

    Chief Executive Officer

  • Herman Steen
    Dribbble

    Chief Bussiness Officer

  • Oscar Kuipers
    Dribbble

    Scientific Advisor